Skip to main content

Advertisement

SpringerLink
Log in

SBRT re-irradiation after prior SBRT in pancreatic cancer—outcomes and a focus on stomach and bowel toxicity

  • Original Research
  • Published:
Journal of Radiation Oncology

Abstract

Objective

Stereotactic body radiotherapy (SBRT) is increasingly used for pancreatic cancer; however, there is a dearth of data guiding its use after prior SBRT.

Methods

We conducted an institutional review board (IRB)–approved retrospective study of patients treated with SBRT for pancreatic cancer on two occasions from 2005 to 2018. Patients were followed for response to treatment and toxicity assessment (Common Terminology Criteria for Adverse Events [CTCAE] version 5). Demographic and survival data for the cohort were described using frequencies, medians, and ranges. Survival analysis was performed using the Kaplan-Meier method.

Results

Twenty-four patients met the inclusion criteria. Local control at 1 year after the second SBRT treatment was 77.2%. Median survival from 1st SBRT course and 2nd SBRT course was 31 months and 13 months, respectively. Most patients were treated with 24 Gy in 3 fractions for their first course and 25 Gy in 5 fractions for their second course. Thirteen patients did not undergo surgery, and 9 had detailed radiation treatment planning data available with non-distorted GI anatomy. For the total summation dose (first and second courses of SBRT combined), the D0.03cc and D1cc to the duodenum received up to 46.1 Gy and 42.3 Gy, respectively, while the stomach received up to D0.03cc of 49.2 Gy and D1cc of 43.8 Gy.

Conclusion

SBRT after prior SBRT for pancreatic cancer is a reasonably safe and efficacious treatment that leads to durable local control and reasonable survival. Retreatment of the duodenum and stomach with a D0.03cc and D1cc of at least 40 Gy may be safe, although more data is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

Research data are stored in an institutional repository and will be shared upon request to the corresponding authors.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590

    Article  PubMed  Google Scholar 

  3. American Cancer Society (2020) Cancer Facts & Figures 2020. American Cancer Society, Atlanta

    Google Scholar 

  4. Hand F, Conlon KC (2019) Pancreatic cancer. Surgery (Oxford) 37:319–326. https://doi.org/10.1016/j.mpsur.2019.03.005

    Article  Google Scholar 

  5. Chadha AS, Khoo A, Aliru ML, Arora HK, Gunther JR, Krishnan S (2016) Recent advances and prospects for multimodality therapy in pancreatic cancer. Semin Radiat Oncol 26:320–337. https://doi.org/10.1016/j.semradonc.2016.05.002

    Article  PubMed  Google Scholar 

  6. Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS, O'Reilly E, Fisher GA, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC (2015) Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121:1128–1137. https://doi.org/10.1002/cncr.29161

    Article  CAS  PubMed  Google Scholar 

  7. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R (2013) Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 86:516–522. https://doi.org/10.1016/j.ijrobp.2013.02.022

    Article  PubMed  Google Scholar 

  8. Rosati LM, Kumar R, Herman JM (2017) Integration of stereotactic body radiation therapy into the multidisciplinary management of pancreatic cancer. Semin Radiat Oncol 27:256–267. https://doi.org/10.1016/j.semradonc.2017.02.005

    Article  PubMed  Google Scholar 

  9. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB, Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406. https://doi.org/10.1056/NEJMoa1809775

    Article  CAS  PubMed  Google Scholar 

  10. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703. https://doi.org/10.1056/NEJMoa1304369

    Article  CAS  Google Scholar 

  11. Golan T, Hammel P, Reni M, van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O’Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317–327. https://doi.org/10.1056/NEJMoa1903387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hammel P, Huguet F, Van Laethem JL et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial. JAMA 315:1844–1853. https://doi.org/10.1001/jama.2016.4324

    Article  CAS  PubMed  Google Scholar 

  13. Kleeff J, Reiser C, Hinz U et al (2007) Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 245:566–572. https://doi.org/10.1097/01.sla.0000245845.06772.7d

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, le DT, Kumar R, Pai JS, Hargens B, Sharabi AB, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM (2013) Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol 4:343–351. https://doi.org/10.3978/j.issn.2078-6891.2013.044

    Article  PubMed  PubMed Central  Google Scholar 

  15. Koong AJ, Toesca DAS, von Eyben R, Pollom EL, Chang DT (2017) Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Adv Radiat Oncol 2:27–36. https://doi.org/10.1016/j.adro.2017.01.003

    Article  PubMed  PubMed Central  Google Scholar 

  16. Dagoglu N, Callery M, Moser J, Tseng J, Kent T, Bullock A, Miksad R, Mancias JD, Mahadevan A (2016) Stereotactic body radiotherapy (SBRT) reirradiation for recurrent pancreas cancer. J Cancer 7:283–288. https://doi.org/10.7150/jca.13295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH (2016) Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys 94:755–765. https://doi.org/10.1016/j.ijrobp.2015.12.003

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA

    Jose F. Duran, Martina Hurwitz, Tobias Chapman & Matthew J. Abrams

  2. Harvard Medical School, Boston, MA, USA

    Jose F. Duran, Martina Hurwitz, Tobias Chapman & Matthew J. Abrams

Authors
  1. Jose F. Duran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Hurwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tobias Chapman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew J. Abrams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew J. Abrams.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

See IRB approval above.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duran, J.F., Hurwitz, M., Chapman, T. et al. SBRT re-irradiation after prior SBRT in pancreatic cancer—outcomes and a focus on stomach and bowel toxicity. J Radiat Oncol 9, 235–241 (2020). https://doi.org/10.1007/s13566-020-00443-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13566-020-00443-x

Keywords

Search

Navigation